Benzinga | Aug 20, 2020 08:10AM EDT

CymaBay Therapeutics Announces Presentations During The Digital International Liver Congress 2020

NEWARK, Calif., Aug. 20, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that two seladelpar presentations will be delivered during the Digital International Liver Congress(tm) 2020 of the European Association for the Study of Liver (EASL) which will be held online August 27th -- 29th.



The presentation titled "Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study,"1 will be delivered by Dr. Cynthia Levy, MD, Associate Professor of Medicine, University of Miami. This electronic presentation will highlight the efficacy, safety, and tolerability of seladelpar treatment over 1 year.

In addition, a preclinical oral presentation2 will highlight the effects of seladelpar in a mouse model of ethanol-induced liver disease from Professor Bernd Schnabl and collaborators at the University of California, San Diego.

Sujal Shah, CEO and President of CymaBay Therapeutics, commented, "We are excited to share the final results from an open-label Phase 2 study of seladelpar in PBC. The data demonstrate that seladelpar retained efficacy and appeared safe and tolerable after 1 year of treatment in patients with PBC. We believe the observed response in this study along with recently reported data from the placebo-controlled ENHANCE study support the evaluation of seladelpar in a new Phase 3 registration study in PBC. We want to extend our sincere gratitude to the patients who have participated in our clinical studies, their families, and the investigators and clinical research team members that support them."

Poster Presentation

August 27th 12:30 PM CEST

FRI133:

1"Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study"

Cynthia Levy, Christopher Bowlus, Guy Neff, Mark G. Swain, Michael Galambos, Marlyn J. Mayo, Aparna Goel, Palak Trivedi, Gideon Hirschfield, Richard Aspinall, Andreas E. Kremer, Stuart C. Gordon, Brian Borg, Stephen Harrison, David Jones, Paul Thuluvath, Yvonne Doerffel, Carmen Stanca, David Sheridan, Bruce Bacon, Christoph Berg, Douglas Thorburn, John Vierling, Mitchell Shiffman, Joseph Odin, Tarek Hassanein,Adam Peyton, Aliya Gulamhusein, Charles Landis, David Bernstein, Lynsey Corless, Marcus-Alexander Woerns, Peter Buggisch, Sandrin Bergheanu, Wendy Chen, Frances Seput-Dingle, Lily Mao, Yu Li, Ke Yang, Elena Muslimova, Yun-Jung Choi, Monika Varga, Klara Dickinson, Pol Boudes, Charles McWherter, Alexandra (Sasha) Steinberg

Oral Presentation

August 27th 12:00 -- 12:15 PM CEST

AS083:

2"The selective PPAR-deltaagonist seladelpar reduces ethanol-induced liver disease by restoring gut barrier function and bile acid homeostasis in mice"

Huikuan Chu, Bei Gao, Yanhan Wang, Lu Jiang, Edward Cable, Bernd Schnabl

A full list of presentations can be found on The Digital International Liver Congress(tm) 2020 website.

The presentations will also be made available on the CymaBay website.